10.1371/journal.pone.0176970.g007
Alok Raghav
Alok
Raghav
Jamal Ahmad
Jamal
Ahmad
Khursheed Alam
Khursheed
Alam
Nonenzymatic glycosylation of human serum albumin and its effect on antibodies profile in patients with diabetes mellitus - Fig 7
Public Library of Science
2017
CKD
Nonenzymatic glycosylation
1737 cm -1. LCMS chromatogram
HSA manifests
mg
carbonyl group
glucose
CML
diabetes mellitus type 2
diabetes mellitus
type 2
glycated-HSA
UV
GDM
antibody
Amide II peak
neo-epitopes generation
complication
peak appearance
carboxymethyl lysine
Modified samples
λ 280 nm
2DM
anincreasein fluorescence intensity
binding enzyme-linked immunosorbent assay
kidney disease
auto-antibodies formation
FTIR results
Conclusions Non-enzymatic glycosylation
anantigen concentration
diabetes mellitus Background Albumin glycation
Results Glycated-HSA
Neo-epitopesagainst In-vitro
Liquid chromatography mass spectrometry
antibodies profile
binding ELISA
amarked increase
1DM
glycation end products
40 day period
Methods Human Serum Albumin
serum albumin
2017-05-17 17:37:12
Figure
https://plos.figshare.com/articles/figure/Nonenzymatic_glycosylation_of_human_serum_albumin_and_its_effect_on_antibodies_profile_in_patients_with_diabetes_mellitus_-_Fig_7/5014130
<p>(a) Inhibition of binding of affinity purified anti-HSA IgG and pre-imune IgG to native HSA. Microtitre plates were coated with native HSA (10 μg/mL). (b) Inhibition of binding of affinity purified anti-glucose-HSA IgG and pre-imune IgG to glucose modified HSA. Microtitre plates were coated with native HSA (10 μg/mL).</p>